Phase 3Recruiting
Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery.
Dexmedetomidine as an Adjuvant for Ultrasound Guided Greater Occipital Nerve Block in Children Undergoing Posterior Fossa Tumor: A Prospective Randomized Controlled Trial
- Sponsor
- Children's Cancer Hospital Egypt 57357 (Academic or other)
- Enrollment
- 260 planned
- Conditions
- Posterior Fossa Tumor
- Interventions
- Bupivacaine 0.25%; Dexmedetomidine 1mcg/kg; Blind greater occipital nerve block; Ultrasound-guided greater occipital nerve block
- Ages
- children, adults
- Registry
- NCT07878156
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to evaluate the effects of ultrasound-guided versus blind greater occipital nerve block (GONB), with or without Dexmedetomidine as an adjuvant, in pediatric patients undergoing posterior fossa tumor excision under general anesthesia. The main questions it aims to answer are: * Does ultrasound-guided GONB improve hemodynamic stability compared with the blind technique? * Does adding dexmedetomidine to GONB affect intraoperative and postoperative opioid consumption, postoperative pain control, and the time to first rescue analgesia? Researchers will compare four groups to evaluate the effects of the nerve block technique and the addition of dexmedetomidine: Group A: Blind GONB using 0.25% bupivacaine. Group B: Blind GONB using 0.25% bupivacaine with dexmedetomidine (1 μg/kg). Group C: Ultrasound-guided GONB using 0.25% bupivacaine. Group D: Ultrasound-guided GONB using 0.25% bupivacaine with dexmedetomidine (1 μg/kg). Participants will be pediatric patients scheduled for elective posterior fossa tumor excision at Children's Cancer Hospital Egypt…
Primary outcomes
- mean arterial pressure (MAP)
History
Study completion expected
Primary completion expected
Registered
Started